Neoadjuvant Approaches to Non-Melanoma Skin Cancer

被引:3
作者
Wilde, David C. [1 ]
Glaun, Mica E. [2 ]
Wong, Michael K. [3 ]
Gross, Neil D. [2 ]
机构
[1] Baylor Coll Med, Bobby R Alford Dept Otolaryngol Head & Neck Surg, 1977 Butler Blvd,Suite E5 200, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA
关键词
neoadjuvant therapy; basal cell carcinoma; cutaneous squamous cell carcinoma; Merkel cell carcinoma; non-melanomatous skin cancer; SQUAMOUS-CELL CARCINOMA; PHASE-II; VISMODEGIB; CHEMOTHERAPY; EFFICACY; SAFETY; HEAD;
D O I
10.3390/cancers15235494
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Non-melanomatous skin cancer (NMSC) is the most incident malignancy worldwide, and management can be difficult in the locally advanced setting. Here, we examine the literature on the use of neoadjuvant systemic therapy prior to surgical excision of NMSC.Abstract Surgery and external-beam radiation therapy are the primary treatment modalities for locally advanced NMSC, but they can lead to impairment of function and disfigurement in sensitive areas such as the head and neck. With the advent of targeted systemic therapies and immunotherapy, physicians have explored the ability to offer neoadjuvant therapy for NMSC in order to reduce surgically induced morbidity. Provided herein is a guide to current applications of neoadjuvant systemic therapies for NMSC and future directions.
引用
收藏
页数:10
相关论文
共 43 条
[1]   The timing of breast and axillary surgery after neoadjuvant chemotherapy for breast cancer [J].
Al-Hilli, Zahraa ;
Boughey, Judy C. .
CHINESE CLINICAL ONCOLOGY, 2016, 5 (03)
[2]   The status of tumor mutational burden and immunotherapy [J].
Anagnostou, Valsamo ;
Bardelli, Alberto ;
Chan, Timothy A. ;
Turajlic, Samra .
NATURE CANCER, 2022, 3 (06) :652-656
[3]   Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study) Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma [J].
Bertrand, Nicolas ;
Guerreschi, Pierre ;
Basset-Seguin, Nicole ;
Saiag, Philippe ;
Dupuy, Alain ;
Dalac-Rat, Sophie ;
Dziwniel, Veronique ;
Depoortere, Cesar ;
Duhamel, Alain ;
Mortier, Laurent .
ECLINICALMEDICINE, 2021, 35
[4]   Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J].
Chalmers, Zachary R. ;
Connelly, Caitlin F. ;
Fabrizio, David ;
Gay, Laurie ;
Ali, Siraj M. ;
Ennis, Riley ;
Schrock, Alexa ;
Campbell, Brittany ;
Shlien, Adam ;
Chmielecki, Juliann ;
Huang, Franklin ;
He, Yuting ;
Sun, James ;
Tabori, Uri ;
Kennedy, Mark ;
Lieber, Daniel S. ;
Roels, Steven ;
White, Jared ;
Otto, Geoffrey A. ;
Ross, Jeffrey S. ;
Garraway, Levi ;
Miller, Vincent A. ;
Stephens, Phillip J. ;
Frampton, Garrett M. .
GENOME MEDICINE, 2017, 9
[5]   Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel [J].
Cowey, Charles Lance ;
Liu, Frank X. ;
Kim, Ruth ;
Boyd, Marley ;
Fulcher, Nicole ;
Krulewicz, Stan ;
Kasturi, Vijay ;
Bhanegaonkar, Abhijeet .
FUTURE ONCOLOGY, 2021, 17 (18) :2339-2350
[6]   First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study [J].
D'Angelo, Sandra P. ;
Lebbe, Celeste ;
Mortier, Laurent ;
Brohl, Andrew S. ;
Fazio, Nicola ;
Grob, Jean-Jacques ;
Prinzi, Natalie ;
Hanna, Glenn J. ;
Hassel, Jessica C. ;
Kiecker, Felix ;
Georges, Sara ;
Ellers-Lenz, Barbara ;
Shah, Parantu ;
Guezel, Gulseren ;
Nghiem, Paul .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
[7]   Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial [J].
D'Angelo, Sandra P. ;
Bhatia, Shailender ;
Brohl, Andrew S. ;
Hamid, Omid ;
Mehnert, Janice M. ;
Terheyden, Patrick ;
Shih, Kent C. ;
Brownell, Isaac ;
Lebbe, Celeste ;
Lewis, Karl D. ;
Linette, Gerald P. ;
Milella, Michele ;
Georges, Sara ;
Shah, Parantu ;
Ellers-Lenz, Barbara ;
Bajars, Marcis ;
Guezel, Guelseren ;
Nghiem, Paul T. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
[8]   Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion [J].
Dummer, R. ;
Ascierto, P. A. ;
Basset-Seguin, N. ;
Dreno, B. ;
Garbe, C. ;
Gutzmer, R. ;
Hauschild, A. ;
Krattinger, R. ;
Lear, J. T. ;
Malvehy, J. ;
Schadendorf, D. ;
Grob, R. J. J. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (09) :1944-1956
[9]   Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study [J].
Dummer, R. ;
Guminksi, A. ;
Gutzmer, R. ;
Lear, J. T. ;
Lewis, K. D. ;
Chang, A. L. S. ;
Combemale, P. ;
Dirix, L. ;
Kaatz, M. ;
Kudchadkar, R. ;
Loquai, C. ;
Plummer, R. ;
Schulze, H. -J. ;
Stratigos, A. J. ;
Trefzer, U. ;
Squittieri, N. ;
Migden, M. R. .
BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (06) :1369-1378
[10]  
Ferrarotto R, 2023, JAMA OTOLARYNGOL, V149, P847, DOI 10.1001/jamaoto.2023.1729